Miniature plumbing fast-tracks drug development

Miniature plumbing fast-tracks drug development
Credit: Lidia Matesic

Sydney researcher Lidia Matesic has developed a technique to speed up the development of nuclear medicines allowing hospitals to not only make nuclear medicine in-house, but also tailor-made to the patient.

In remote hospitals, this would also allow a larger variety of these pharmaceuticals to be used.

"We have some nuclear medicines that work extremely well for particular diseases, like radiotherapy for cancer," says Lidia. "But we need more-specific nuclear medicines for other diseases, such as Alzheimer's."

These can take years to develop – but faster reactions and processes would allow researchers to develop new nuclear medicines faster.

Lidia is working to speed up these processes using 'microfluidic technology' which makes faster by using less liquid. Down from millilitres to millionths of a litre.

These contain tiny, intricate structures of tubes that could fit easily within a matchbox. The components of the machinery are miniscule – only hundredths of a millimetre in dimension.

Her lab at the Australian Nuclear Science and Technology Organisation (ANSTO) in Sydney is the only one of its kind in the Southern Hemisphere.

"Using this technology, it's possible we could move into pre-clinical trials in weeks – and towards human trials of a new medicine much faster than with previous ."

The concept, known as dose-on-demand, is particularly important with radiopharmaceuticals because the active radioactive components of the decay quickly (in as little as minutes or a few hours).

The research is published in Nuclear Medicine and Biology.

Provided by Freshscience

Citation: Miniature plumbing fast-tracks drug development (2017, June 29) retrieved 19 June 2024 from https://phys.org/news/2017-06-miniature-plumbing-fast-tracks-drug.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

FDA approves drugs more quickly than peer agency in Europe: study

1 shares

Feedback to editors